Illuminating BiDil  

Oleh:

[s.n]

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 8 (Agu. 2005), page 903-904.
Topik: therapy; illuminating BiDil

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.4 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

BiDil is a recently approved therapy indicated for congestive heart failure patients already taking standard treatments. It is not a new drug, It is a combination of two existing drugs isosorbide dinitrate and hydralazine already marketed separately as generic. What is new about BiDil is its scientifically dubious distinction as the first drug ever approved in the united states for exclusive use in african americans. But BiDil was not always destined for african american hearts. its transformation into an ethnically targeted medicine is relatively recent and follows a long history of clinical testing for heart disease into the general population...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali